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Abstract 
The fundamentals of this research were to exploit non-ionic surfactant technology for delivery and 
administration of vaccine antigens across the oral route and to gain a better understanding of vaccine 
trafficking. Using a newly developed method for manufacture of non-ionic surfactant vesicles 
(niosomes and bilosomes) lower process temperatures were adopted thus reducing antigen exposure 
to potentially damaging conditions. Vesicles prepared by this method offered high protection to 
enzymatic degradation, with only ~10% antigen loss measured when vesicles incorporating antigen 
were exposed to enzyme digestion. Interestingly, when formulated using this new production method, 
the addition of bile salt to the vesicles offered no advantage in terms of stability within simulated 
gastro-intestinal conditions. Considering their ability to deliver antigen to their target site, results 
demonstrated that incorporation of antigen within vesicles enhanced delivery and targeting of the 
antigen to the Peyer’s Patch, again with niosomes and bilosomes offering similar efficiency. Delivery 
to both the Peyer’s patches and mesentery lymphatics was shown to be dose dependent at lower 
concentrations, with saturation kinetics applying at higher concentrations. This demonstrates that in 
the formulation of vaccine delivery systems the lipid/antigen dose ratio is not only a key factor in 
production cost, but equally is a key factor in the kinetics of delivery and targeting of a vaccine system.  
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Introduction 
Mucosal sites are primary access points for most human pathogens, therefore the induction of 
mucosal immunity plays an important role to prevent pathogen entry and to prevent infection [1-3]. 
However, despite the oral route being easily accessible and offering good patient compliance, it is not 
always feasible to administer vaccines via this route due to problems of degradation of the vaccines 
in the gastro-intestinal tract (GIT) [4]. In addition, the residence time of vaccines at the immune 
induction sites within the GIT (Peyer's Patches) is short due to GI transit. The target site for mucosal 
vaccine delivery systems are the M cells located within Peyer's patches which are randomly distributed 
across the mucosa of the GIT, mainly in the jejunum [5]. Due to the short exposure time of the vaccine 
to the Peyer's patches, higher doses or an increase in dosing frequency are often required to supply 
sufficient antigen delivery to elicit an immune response [6]. However, this strategy of increasing dosing 
could potentially lead to reduced secretion of antigen specific IgA levels, due to increased systemic 
tolerance to the vaccine [7].  
 
Currently non-ionic surfactant vesicle carrier systems, such as niosomes or bilosomes, are being 
employed to encapsulate/associate vaccine antigens and administer via the oral route. The addition 
of bile salts (to form bilosomes) has been proposed to enhance antigen delivery by offering increased 
protection and retention of the antigen within the bilosomes when subjected to intestinal media 
containing bile acids, thus preventing premature release of antigen prior to reaching the target sites 
[1]. Commonly, the methods used to form these vesicles involves antigens being heated to 60 °C or 
several freeze thaw cycles to prepare the vaccine delivery systems [1, 8] which can be detrimental. 
For example, Statens Serum India have shown that after three freeze thaw cycles vaccines such as 
Tetanus, Diphtheria and Pertussis lose up to 60% potency [9]. Similarly, the potency of a vaccine can 
be related to exposure to excess temperatures, therefore it is essential to maintain vaccine 
components at their ideal temperatures for maximum potency [10, 11].  
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Given these issues, it is essential that vaccines are not subjected to freeze thaw cycles or elevated 
temperatures as this could diminish the potency of the vaccine. Therefore we have developed a new 
protocol for the preparation non-ionic surfactant vesicles (with and without the addition of bile salts) 
at a lower process temperature incorporating thermo sensitive antigens.  
 
This work follows on from our previously published work [12] where we studied the influence of 
various bilosome formulation parameters on the systemic efficacies of oral vaccine delivery. In these 
previously reported studies we demonstrated that the DCP content is a key formulation parameter 
for controlling both the zeta potential and pH of suspension and the bile salt content is the major 
bilosome size dictating parameter.  Furthermore it was demonstrated that the larger bilosome system 
of 6 µm diameter lead to enhanced uptake within the target Peyer's patches.  Importantly, in an 
influenza challenge experiment it was shown that the orally administered bilosome system containing 
influenza antigen (rHA) is capable of reducing median temperature differential change and leads to 
significant reduction in viral cell load counts. In this paper we demonstrate a new method for bilosome 
production which offers an increase in antigen protection/retention within vesicles. Furthermore we 
demonstrate that using this method, the addition of bile salts to the formulation offers no notable 
advantage in terms of antigen retention or delivery after oral administration.  
 
Materials and Methods 
To form the vesicles the surfactants monopalmitoyl glycerol (MPG; Larodan AG, Sweden), synthetic 
cholesterol (Chol), dicetyl phosphate (DCP) and sodium deoxycholate (bile salt) (Sigma-Aldrich, UK) 
were used. The buffers were made up of sodium bicarbonate (Sigma-Aldrich, UK) at pH 7.6, where 
hydrochloric acid and sodium hydroxide (NaOH) (Sigma-Aldrich, UK) was used for pH adjustments. For 
the antigen a recombinant H3N2 sub-unit protein (Immune Tech, USA) was used. 
 
Preparation of niosomes and bilosomes 
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Vesicles were prepared based on a modified method [1]. Briefly, a paraffin oil bath was set up at 120 
°C and a water bath at 30 °C.  A 25 mM sodium bicarbonate buffer (pH 7.6) was prepared containing 
the H3N2 antigen and in the case of bilosomes 100 mM sodium deoxycholate (bile salt) was also 
added. Appropriate molar ratios of the lipids MPG, Chol and DCP (5:4:1 respectively) were weighed 
and placed in a 25 mL flat bottom glass beaker and the mixture was melted by heating at 120 °C for 
10 minutes with occasional mixing. The molten lipids (308.5 mg) at 120 °C was immediately removed 
from the oil bath and an emulsion was created by the addition of the pre-incubated antigen buffered 
stock solution (preheated to 30 °C) and immediately homogenised (using an emulsion head) for 10 
minutes at 8000 rpm. Once homogenisation had finished, the bilosome formulation was allowed to 
cool to 30 °C, and left for 2 hours in an incubator/shaker at 220 rpm.  
 
Characterisation of vesicles. 
The size of the vesicles was determined using laser diffraction on a sympatec 2005 (Helos/BF) analyser. 
20 µL aliquots of the vesicle suspension was diluted into the cuvette with 40 mL double distilled water. 
The zeta potential was measured in 1.5 mL double distilled water at 25 °C on a Zeta Plus Brookhaven 
Instrument. 20 µL of the bilosome suspension was mixed in 1.5 mL double distilled water and then 
analysed. The pH of the vesicle suspension was determined using a pH meter where the tip was placed 
into the vesicle suspension and left for a few minutes.  
Removal of non-incorporated antigen 
For quantification of antigen association, ultra-centrifugation of the formulations was required to 
isolate vesicles with entrapped antigen, from non-incorporated antigen. To achieve this, 300 µL 
aliquots of sample was diluted in a Beckman 3.9 mL Polo-allomer tube and centrifuged twice at 
354,000 X g for 45 minutes at 4 °C with the acceleration set at 8 (Slowest) and the deceleration at 
coast.  
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Radiolabelling of H3N2 antigen 
To quantify antigen incorporation, antigen release and trypsin digestion, the antigen was radio-
labelled using 125I. To achieve this antigen stock solutions were prepared as 100 µg (1mg/mL) in PBS 
stock and 40 µL (40 µg) placed into an iodination tube (Pierce Biotechnology) with 2 Mbq for 1 hour 
and subsequently separated from non-labelled antigen by column chromatography using sephadex 
G75 beads [12]. 
Trypsin Digestion 
Vesicles were prepared with radiolabelled antigen and an initial antigen association was calculated by 
centrifugation. Trypsinisation studies were carried out by incubating aliquots of the sample with 100 
µg/mL trypsin for a period of 30 and 60 minutes at 37 °C to remove any adsorbed antigen. The samples 
were then centrifuged to determine surface adsorption of the antigen [14]. 
Stability of the vesicles in simulated fasted gastric and intestinal medium 
Fasted state simulated gastric media (50 mL) was prepared using a 34.2 mM NaCl solution in 50 mL 
HPLC water at pH 1.2 adjusted with 1 M HCl. Pepsin (40 mg) was then added, followed by sodium 
taurocholate (2.15 mg) and phosphatidylcholine (0.76 mg) in 50 mL at 37 °C [15].  
Fasted state simulated intestinal media (50 mL) was prepared by a 50 mM PBS solution in 50 mL HPLC 
water at pH 8.5, adjusted with 1 M NaOH, and sodium glycodeoxycholate (180 mg) and 
phosphatidylcholine (34 mg) dissolved in the solution at 37 °C [16]. To establish the effect of these 
conditions on vesicle attributes, 400 µL of the vesicle formulations was added to 3.6 mL of Fasted 
gastric medium as a 1:10 dilution. The formulations were tested for vesicle size and zeta potential at 
specific time intervals. The gastric to intestinal phase was carried out by centrifuging 3.9 mL of the 
formulations from the gastric period and then resuspending the pellet in fasted intestinal fluid and 
was then tested at the stated time points. To measure antigen retention in these conditions, radio-
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labelled antigen was incorporated within the formulations and antigen retention tracked in the above 
conditions by ultracentrifugation (Beckman, Ultima XP) at 354, 000 X g. 
In vivo biodistribution protocol 
Inbred female Balb/c (6-10 weeks of age) mice were housed in cages within a laminar flow safety 
enclosure and provided with irradiated food and filtered drinking water. Experimentation adhered to 
the 1986 Scientific Procedures Act (UK). All protocols have been subject to ethical review and were 
carried out in a designated establishment. 200 µL doses of the formulations, which were washed to 
remove unentrapped radiolabelled antigen, were administered orally to Balb/c mice (n=4). Animals 
were terminated at various time points, organs collected and analysed for both 125I (to quantify 
antigen) and 3H (to quantify vesicles), which were used as a radio-active tracker for vesicles by 
incorporating 3H-cholesterol in the formulation.  
Gamma vials were pre-labelled and individual tissues/organs were weighed and individually placed 
into the gamma vials. To the gamma vials 1.5 mL of solvable was added to digest the tissues. Once the 
solvable was added to the vials they were then placed onto the gamma counter to record the 125I-
antigen levels. The vials were then placed into an incubator at 50 °C overnight to dissolve the tissues. 
Once the tissues had dissolved the contents of the gamma vials were transferred to 20 mL scintillation 
vials where 200 µL hydrogen peroxide was added to each vial to bleach the samples. The vials were 
left overnight once again to wait for the gas to disappear and 10 mL of scintillation fluid (Ultima Gold) 
was added to form an emulsion. The vials were then counted on the scintillation counter which will 
represent the counts for the vesicles at each site. 
Confocal laser scanning microscopy 
Niosome vesicles were prepared incorporating a Dil-C lipid dye which was co-melted during the lipid 
melting phase of the method. The antigen was pre-labelled with a fluorescent flamma fluor FPR-648 
(Bio Acts) which was carried out by incubating the fluorescent marker with the antigen and then 
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separated using a P-10 (10Kd MWCO) centrifugation tube to remove unbound marker. The niosome 
vesicles were prepared and administered orally to Balb-C mice and after 30 minutes the Peyer's Patch 
was spliced along with the mesenteric lymph tissue to locate the vesicles and the antigen. Samples 
were then analysed on a Leica Confocal microscope using a 63x objective. 
Statistical analysis 
The results within this study are given as the geometric mean ± S.D. unless stated otherwise. The 
statistics were carried out using ANOVA and a probability factor of less than 0.05 (P < 0.05) was 
considered to represent statistically significant difference. 
 
Results and Discussion 
Physical characteristics of vesicles along the Gastro Intestinal Tract 
Non- ionic surfactant based vesicles have provided effective immunity in various animal models such 
as mice and ferrets after oral administration [12, 17].  The oral route provides a challenging 
environment for delivery of antigens including low pH, digestive/ gastric enzymes the poor absorption 
and the rapid transit [18]. As a result, it is important to ensure that the antigen and carrier system 
remains intact during transit through the GI tract until it reaches the target site. Therefore to 
investigate this, vesicles were subjected to simulated gastric media (pH 1.2) and either transfected 
from gastric media to simulated intestinal media (pH 8.6) or placed directly into simulated intestinal 
media and at various time points the vesicles were analysed for their characteristics (vesicle size, zeta 
potential and antigen retention; Figure 1). 
Results (Figure 1A) show that the niosome preparation significantly decreases (p< 0.05) in volume 
mean diameter (VMD) from 6.54 ± 0.04 µm (t = 0 h; prior to exposure to gastric media) to 5.46 ± 0.05 
µm after 1 h gastric media, down to 3.57 ± 0.03 µm after 4 hours in GSIF medium. In contrast, bilosome 
vesicles significantly increase in VMD (p< 0.05) from 6.19 ± 0.04 µm to 9.13 ± 0.31 µm when in gastric 
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medium for 1 h yet they return to their original vesicle size when placed back in SIF (to 6.11 ± 1.27 µm; 
t= 4 h; Figure 1A). Directly adding the vesicles into SIF made no significant difference to the size of the 
niosomes or the bilosomes (Figure 1A).  
Considering the vesicle zeta potential, results (Figure 1B) show that whilst the both niosome and 
bilosome vesicles are highly negative in nature at neutral pH (t = 0 h) as would be expected given their 
DCP content, in media at pH 1.2 a notable reduction in zeta potential occurs (from ~ -100 mV to -35 
mV; Figure 1B) and when in conditions as would be at the site of uptake (intestinal regions containing 
Peyer's Patches; pH 8.6), the zeta returns to its original value of -100 mV (Figure 1B). This trend is 
observed for both niosomal and bilosome formulations. 
 
These changes in size may be due to differences in osmotic pressure and/or flocculation properties of 
vesicles within the various media, particularly given the changes in zeta potential resulting from the 
differences in electrolytes present. Similar to these findings, an increase in carrier size has also been 
observed by Mane and Muro (2012) where nanocarriers containing IgG incubated in acidic simulated 
gastric fluid showed an increase in carrier size which was not observed in neutral simulated intestinal 
fluids [19]. The authors attributed the increase in size to be due to the degradation of IgG resulting 
from pH changes which caused aggregation. Given that studies have shown the proposed 
transparacellular uptake of particles within the Peyer's patches is limited to below 10 µm [20-22] it is 
important that the vesicle size and surface characteristics remain appropriate for this route. In 
addition, it has been suggested that the retention of particles within the Peyer's patches is optimum 
for vesicles 4 -10 µm in size, whilst vesicles below 3 µm translocate into the lymphoid tissue [21, 23, 
17]. This is also supported by a study using microspheres by Tabata et al, (1996) which has shown that 
particles within the 5-10 µm induced a mucosal immune response whereas smaller vesicles migrate 
into the lymphatics resulting in systemic immunity [24]. The results in Fig 1A and B show that whilst 
the vesicle size and zeta potential is dependent on the media the vesicles were suspended in, when 
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suspended in conditions simulated to represent the environment of the target area for vaccine uptake 
the vesicles fall within an acceptable range for uptake and retention within the Peyer's patches. 
Whilst the physico-chemical characteristics were appropriate for particulate uptake by the Peyer’s 
patch, it is also pivitol that the vesicles are able to carry antigen to this target site. To consider this, 
the H3N2 antigen was radiolabelled and incorporated into the niosome and bilosomes vesicles and 
antigen retention studies were carried out. Considering initial antigen (Figure 1C), there was no 
notable difference in antigen incorporation between niosomes and bilosomes (39.21 ± 2.72 vs 32.5 ± 
2.9 % for niosomes and bilosomes respectively; Figure 1C). Considering the impact of the GI 
environment, results in figure 1C indicate that after 15 min in gastric medium (pH 1.2) niosome antigen 
retention decreased by approximately 10 % (from 39.21 ± 2.72  to 28.04 ± 0.95 %; Figure 1C) and then 
remained around this level for up to 60 min in gastric media. In contrast, bilosomes show no significant 
loss in antigen retention when incubated in gastric media for up to 60 min (maintaining their antigen 
retention levels of ~32 %; Figure 1C). When the vesicles are taken from gastric to intestinal medium, 
both the niosome and bilosome formulations showed reductions in antigen retention (Figure 1C), with 
only ~ 10 to 15 % of the antigen being retained.  This reduction in antigen loading was a result of the 
vesicles being suspended in the higher pH intestinal media, with prior exposure to gastric media 
making no notable difference as demonstrated by the fact there was no difference in antigen loading 
for vesicles first suspended in gastric media and then transferred to SIF, compared with vesicles 
suspended directly into SIF (Figure 1C). 
To consider the special location of the antigen and their ability to protect antigen from enzymatic 
degradation, both niosomes and bilosomes were subjected to protein (trypsin) digestion. Figure 2 
shows that after incubation with trypsin, both formulations show low antigen loss (~5 %) suggesting 
that in both systems the antigen is predominately located within the vesicles (and hence protected 
from protease digestion). Considering the results of Figure 1C and 2, the choice of bilosome over 
niosome gives no advantage with antigen recovery being similar in both formulations. This is in 
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contrast to previous studies by Conacher et al, (2001) where they demonstrated that bilosomes 
retained a higher percentage of their entrapped bovine serum albumin compared to the 
corresponding niosomes when subjected to 20 mM bile salt concentrations [1]. However, they 
confirmed that the presence of bile salts within the formulations did not increase adjuvant activity 
and stimulated similar immune responses to niosomes.  
In this present study, the method of manufacture of the vesicles has been modified to reduce the 
temperatures used in the manufacturing process and also to potentially promote higher loading within 
the aqueous core of the vesicles by adding the antigen at an earlier stage during the homogenisation 
procedure. Therefore, by modification of the manufacture method (Figure 3), the results in figure 1 
and 2 suggest that the addition of bile salts does not improve antigen protection. Indeed in previous 
studies from our laboratory [17] using bilosomes formulated by the method of Conacher et al., (2001) 
whilst in general vesicle size and zeta potential were similar for the two types of manufacture, we 
have measured a sharp decline in antigen recovery when placed into the SIF after gastric exposure; in 
these previous studies [17] only ~ 7-8 % antigen was associated with bilosomes (of comparable 
surfactant composition), compared to significantly higher (p< 0.05) antigen association of ~ 10-15 % 
(Figure 1C) when bilosomes are formulated using the currently reported bilosome production method 
(which adopts lower temperatures and includes antigen at the start within the aqueous buffer; Figure 
3). 
Visualisation of vesicles in GI transit via confocal laser scanning microscopy  
Within this study we have shown that the vesicles remain within the desired size range 5-10 µm after 
subjecting to simulated gastric and intestinal conditions. To obtain a greater understanding of 
antigen/vesicle transport through the GIT, the bilayers of the vesicles were fluorescently labelled with 
a lipid dye (Dil-C) and the antigen was fluorescently labelled with a flourophore dye. Figure 4 
represents the imaging process from manufacturing of the vesicles to the site of uptake of the vesicles/ 
antigen in-vivo.  
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As represented within figure 4, the vesicles have a strong red colour (Figure 4A) and the antigen 
(labelled blue) resides within the aqueous core of the vesicles, which can be compared to vesicles 
without antigen that show a black aqueous core. These fluorescently labelled vesicles were 
administered via oral gauvage (0.2 mL dose; [25, 26]) and subsequently after 30 minutes tissues were 
excised and analysed via microscopy to locate the vesicles. Figure 4C shows the removed GIT 30 min 
after oral administration of the vesicles, and upon excising of the Peyer's patch intact vesicles that are 
spherical and between 5-10 µm in size can be observed in large numbers when on a low magnification 
(Figure 4D). Upon increased magnification, and 40 µm deep within the tissue, a 5 µm vesicle is clearly 
visible (Figure 4E), suggesting that the Peyer's patches uptake the vesicles. Moving from the Peyer's 
patches to the underlying mesenteric lymph tissue (Figure 4F) once again fluorescence is visible with 
a green autoflourescence appearing from collagen within the capillary network within the mesentery.  
In-Vivo biodistribution of vesicles and their associated antigen 
Dual radiolabelling techniques have previously been used to follow the movement of vaccine antigens 
and their delivery systems (e.g. [12]). It is important to understand the biodistribution of mucosal 
vaccines administered orally as they are subject to dilution in mucosal secretions, captured within the 
mucus and attacked by the mucosal proteases and enzymes with the largest obstacle being exclusion 
by the epithelial barriers [27]. Within this study, the location and biodistribution of H3N2 antigen (125I) 
and the vesicle carrier system (3H- Chol) was used to consider the uptake of vesicle and antigen and 
to determine the residence time of the vaccine within the GIT. Again oral gauvage volume of 0.2 mL 
was used. 
To consider if the addition of bile salt to the niosomes prepared by the revised method (as outlined in 
figure 3) offered advantages in terms of antigen delivery, the biodistribution of bilosome and niosome 
formulations were analysed at 0.5, 1 and 4 h after administration. Throughout the study the blood, 
spleen, kidneys and liver had only trace levels of antigen and vesicles detectable (data not shown) with 
the majority of the both being located in the stomach, small intestine, the colon and cecum (Figure 5). 
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When considering carrier (niosomes or bilosomes) distribution, the majority of the dose was located 
within the stomach and small intestine (Figure 5A); around 30 % of the initial dose was detected within 
the small intestine after 0.5 h with no significant difference between the two formulations. By 4 h the 
levels in the small intestine had decreased with higher levels being detected in the cecum and colon, 
as would be expected for the formulations as they transit through the GIT. Again there was no 
significant difference in the profiles of the two formulations (Figure 5A). Considering the transit of the 
associated antigen (Figure 5B), whilst comparable levels of ‘free’ and vesicle-incorporated antigen are 
found within the stomach, significantly lower levels (< 10 % of initial dose) for ‘free’ antigen was 
detected in the small intestine after 1 h compared to antigen carried by vesicles (Figure 5B). Moreover 
these higher levels of antigen recovery correlated with vesicle recovery as it transits from the stomach 
and small intestine, and then over time the dose progressed down the GIT to the cecum and colon 
(Figure 5A and B) suggesting the antigen has remained associated with the vesicles. Again there was 
no significant difference in the profile of the niosome and bilosome delivered antigen across the study 
(Figure 5B).  
Targeting of the vaccines to the Peyer's Patch and mesenteric lymph tissue 
The Peyer’s patches are located at the antimesenteric border of the intestine where they appear as 
nodular white masses (1.5 – 3.0 mm) and are key to antigen uptake and induction of immunity [28]. 
The Peyer's patches are an attractive route for targeted delivery as this provides a direct route for 
antigen to reach the lymphatic system where first pass metabolism is avoided and the chances of 
cellular rejection are reduced due to the M cells not expressing P-glycoprotein efflux pumps [29, 30]. 
Furthermore, the Peyer's patches, in comparison to the rest of the GI mucosa, possess minimal 
mucosal coating where transcytotic activity is high [31, 32]. To consider targeting of the vaccine system 
to the Peyer’s patch approximately 8-11 Peyer's patches recovered (in line with literature a number 
of 6-12 patches; [28]). Figure 6A shows that using a vesicle carrier system made no significant 
difference to the uptake of antigen within the Peyer’s patch and there was no significant difference in 
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carrier uptake between the niosomes and bilosomes (which was in the range of 1-5 %; Figure 6A). 
However in terms of antigen recovery within the mesenteric lymph tissue, the use of a vesicular 
delivery system significantly (P < 0.01) increased antigen delivery, yet the choice of carrier (niosomes 
versus bilosomes) made no significant difference to either antigen or carrier localisation within the 
mesenteric lymph tissue (Figure 6B). 
The vesicles used within this study were shown (Figure 1) to remain within the desired  size range for 
increased uptake and retention within the Peyer’s patches [17]. Figure 6 indicates that the vesicles 
and antigen are able to penetrate and reside within the lymph tissue for a period of 4 hours. This is 
beneficial as the vesicles which remain in the Peyer's patches offer increased mucosal immunity 
whereas the increased antigen and vesicles within the mesentery is more likely to induce systemic 
immunity thus, offering both mucosal and systemic immunity [24]. In addition, Neutra and Kozlowski 
(2006) determine that antigens delivered to mucosal sites within the small intestine offer greater IgA 
secretions which are a characteristic of mucosal immunity compared to antigen delivery via routes 
such as nasally where a systemic antibody response is achieved, due to the migration of antigen to the 
draining lymph nodes [27].  
The impact of carrier dose on antigen update  
Based on the biodistribution study a question arose; is uptake within the Peyer’s patches limited in 
terms of saturation and uptake? To address this, a study considering varying doses of the vaccine was 
carried out which involved four groups of a) double dose (antigen 180 µg/mL, lipid 27 mg/mL), b) a 
standard dose from Figure 5 & 6 (antigen 90 µg/mL, lipid 13.5 mg/mL), c) a half dose (antigen 45 
µg/mL, lipid 6.75 mg/mL) and d) a quarter dose (antigen 22.5 µg/mL, lipid 3.375 mg/mL) and uptake 
of vesicles and antigen at the target site Peyer’s patches and Mesenteric lymph tissue considered. 
Based on the biodistribution study the organs removed for the following study focussed specifically 
on the GI tract which included the stomach, Mesenteric lymph tissue, Peyer’s patches, small intestine, 
colon and cecum (Figure 7).  
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Results from the study (Figure 7) show no significant differences in percentage antigen or vesicle 
recovery between different dose concentrations in the organs collected after a 30 min time point and 
overall percentage recovery of antigen is comparable (40-70 %) between all doses administered based 
on the initial dose (Figure 7A). The vesicle recovery (Figure 7B) between the organs is also comparable, 
with no significant differences suggesting that the clearance rate and the gastric emptying time was 
not formulation dose dependent over the range tested. Gastric emptying time has been attributed to 
the fed or fasted state of the GIT, where the gastric emptying time (T ½) in the fasted state is up to 2 
± 1 min compared to a fed state T ½ of 17± 2 min in a mouse model [33].  Whilst both the niosomes 
and bilosomes were shown to have similar stability, previous studies have shown that the stability of 
lipidic systems can influence gastric clearance. For example, Marciani et al, (2009) study the stability 
of lipid emulsions on gastric emptying; they demonstrate variations in gastric emptying times with 
500mL of (15% w/w) [13C] palmitate-enriched olive oil-in-water emulsion meals depending on the lipid 
composition [34].  Acid-unstable lipid emulsions broke down and rapidly layered in the stomach 
compared to acid-stable lipid emulsions which had significantly slower gastric emptying. The acid-
stable emulsion emptied from the stomach linearly compared to the acid-unstable emulsion which 
emptied exponentially. The authors attributed this to acid-stable emulsion inducing increased fullness, 
decreased hunger and decreased appetite, where it was concluded that it is possible to delay gastric 
emptying and increase satiety by stabilising the intragastric distribution of lipid emulsions against the 
gastric acid environment [34].   
When considering concentrations of lipid and antigen uptake rather than percentage dose (Figure 8), 
there is a general trend of increased concentrations of antigen and carrier within both the Peyer’s 
Patches and the mesentery lymph tissue as the dose increases up to 90 µg/mL antigen, 13.5 mg/mL 
lipid (figure 8). This suggests that increasing the dose of a vaccine can improve delivery to the Peyer’s 
patch and mesentery lymphatics. However a saturation point may be reached as shown in figure 8B, 
where the increase in the dose to 180 µg/mL antigen / 27 mg/mL lipid did not significantly increase 
delivery. Using lipid-based delivery systems has been demonstrated to increase the lymphatic 
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transport and absorption of drugs in other studies. For example, lymphatic uptake of halofantrine was 
increased when it was incorporated within a self-microemulsifying drug delivery system based on 
structured triglycerides containing medium and long chain fatty acids [35, 36]. The lipid content within 
the drug delivery system was able to trigger sufficient lymphatic transport of halofantrine thus, 
increasing bioavailability. Saturation of uptake via this route has also been demonstrated by Florence 
et al, (2000) using polylysine dendrimer coated with a lipid surface; their results showed maximum 
uptake within Peyer's patches of 1 % after a period of 3 hours which was not increased upon increased 
dose concentration levels [37].  
 
Conclusions 
The proposed method of producing vesicles to protect thermolabile antigens by lowering the process 
temperatures shows that antigen can be associated and entrapped within non-ionic surfactant 
vesicles. Confocal laser scanning microscopy confirms that the vesicles are spherical in nature and the 
vesicles meet the criteria of being within the optimum size range and charge for increased uptake 
within the target site of the Peyer's Patches. The biodistribution studies demonstrate that by adopting 
the new production method for these non-ionic surfactant vesicles, the necessity of the addition of 
bile salts to enhance protection and delivery is circumvented as both antigen retention and antigen 
delivery to the target site after oral administration was comparable. However, uptake at the target 
site was shown to be dose-rate limited with saturated uptake becoming apparent and therefore 
antigen to lipid dose ratio may be a key factor not only in terms of cost effectiveness but also in vaccine 
efficacy, and thus requires further consideration in the assessment of the design of carrier-mediated 
immunisation.  
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Figure legends: 
 
Figure 1: Characterisation of niosomes and bilosomes when subjected to GI fluids at various time 
points for A) Vesicle size, B) zeta potential and C) antigen retention within the vesicles (n=3).  
 22
Figure 2: Antigen protection from enzyme digestion offered by incorporation within vesicles by 
trypsinisation (n=3).  
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Figure 3: Schematic representing method modifications and corresponding characterisation data 
between bilosomes produced via the pre-formed vesicle method as outlined Conacher et al., 2001 or 
the method outlined within the Method section where antigen is incorporated within the vesicles in-
situ.  
 24
Figure 4: Confocal laser light microscopy images of niosome vesicles labelled with a lipid Dil-C dye and 
antigen labelled with a Flammaflour FPR 648 dye. Stages include A) vesicle emulsion upon formation, 
B) analysis of vesicles representing vesicles corresponding to vesicle size data showing antigen 
location, C) vesicles in GI transit, D) spherical vesicles within Peyer's patches, E) vesicle within Peyer's 
patch 40 µm deep and F) mesenteric lymph tissue fluorescence.  
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Figure 5:  In vivo trafficking of antigen and vesicles along the GIT after oral gavage where A) represents 
the niosomes or bilosomes radiolabelled with 3H-Cholesterol and B) represents H3N2 antigen 
radiolabelled with I125  and dosed without a carrier system or in associated with bilosomes or niosomes 
(n=4 at each time point).  
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Figure 6: Recovery of antigen and vesicles based on initial dose at t= 1h within A) Peyer's patches and 
B) Mesenteric Lymph Tissue (n=4).  
 
Figure 7: In vivo saturation study of various dose concentrations representing antigen and vesicle 
recovery within the organs selected; A) antigen recovery, B) vesicle carrier recovery (n=4). 
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Figure 8: Representation of dose recovery per mL at site of uptake for various dose concentrations of 
the formulation within Peyer’s patches and mesenteric lymph tissue; A) antigen dose and B) lipid dose 
(n=4).  
 
 
